
    
      The conducted study will be randomized and single-blind (patients). After signing informed
      consent, the participants will be randomized in one of three groups: - placebo - baclofen 30
      mg/day - baclofen 60 mg/day. The participants will be given a first administration after
      which the participant can receive Clinical Institute Withdrawal Assessment (CIWA-ar) score
      triggered diazepam, frequently assessed for at least 7 days. The primary outcome measure is
      the number of participants who received additional diazepam during these 7 days. The
      secondary outcome measure is the amount of diazepam received per group.
    
  